Tvardi Therapeutics adds Sujal Shah to its Board of Directors

– USA, TX –  Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Sujal Shah, CEO of CymaBay Therapeutics, to its Board of Directors.

“Tvardi is thrilled to have Sujal join our board,” said Board chairman, Dr. Ronald DePinho. “His experience in navigating financial markets and investors as well as operating and scaling a biotech company are incredibly relevant as Tvardi grows and becomes successful.”

About Sujal Shah

Mr. Shah brings two decades of experience as an operator and advisor in the biotechnology sector to the Tvardi Board. Since 2017, he has been President and CEO at CymaBay Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for patients with liver and other chronic diseases. Previously, he served as CFO of CymaBay, taking the company public in 2014.

Before CymaBay, Mr. Shah was a healthcare investment banker for Citigroup as well as Credit Suisse, where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused on life sciences.

Mr. Shah commented, “Tvardi is at an exciting juncture in its brief history as it advances its STAT3 platform across multiple clinical indications including cancer and fibrosis. I look forward to working alongside the Board and management during this growth phase of the company.”

Mr. Shah also serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. He received an M.B.A. from Carnegie Mellon University Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.

About Tvardi Therapeutics, Inc.

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3. STAT3 is a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic diseases. Early clinical studies have shown that the company’s lead asset in cancer, TTI-101, is well tolerated and has clinical activity across a broad range of tumors including multiple durable responses.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.